TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06652633: Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

Sponsor: Lakefront Biotherapeutics NV · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 546 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT06652633 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06652633 Rescue Dossier →